Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Stem Cell Research & Therapy
  4. Fast Track Articles
  5. Fast Track Article
image of Mechanism of Zhengsui Wan in the Treatment of Acute Lymphoblastic Leukemia Based on Network Pharmacology and Experimental Validation

Abstract

Background

Zhengsui Wan (ZSW) is a commonly used traditional Chinese medicine formula for treating Acute Lymphatic Leukemia (ALL) in our institution, and it has shown potential efficacy. However, its mechanism of action (MoA) remains unclear. In this study, we systematically explored the ZSW in ALL ( and ) using network pharmacology and molecular docking techniques.

Methods

Mass spectrometry was conducted to analyze possible active components in ZSW. BALB/c mice were treated by ZSW aqueous decoction, and mesenchymal stem cells (MSCs) were extracted for proteomic analysis to evaluate differentially expressed proteins. Moreover, proteins associated with acute lymphoblastic leukemia in SwissTargetPrediction and GeneCards databases were screened, and they intersected with differentially expressed proteins to obtain potential targets for ZSW. Protein interactions were constructed for the selected targets. Then, we performed GO and KEGG enrichment analysis on its basis and screened the core target through K-core. We validated it by molecular docking with the top three actives in the molecular network in degree value. Finally, we detected the regulation of ICAM1 in MSCs by ZSW by qRT-PCR.

Results

We detected 182 active ingredients in ZSW and identified 725 differential proteins in ZSW-treated mice, of which 25 were potential targets. Furthermore, MMP2, ICAM1, PSEN1, SLC9A1, and MMP14 were identified as core targets using the PPI network and K-core screening. Moreover, ZSW significantly downregulated ICAM1 expression in MSCs. GO and KEGG enrichment analyses showed that the results of ZSW were coordinated through immunomodulatory, inflammation-related, and drug resistance-related genes, including the PI3K-Akt, cAMP, and Wnt signaling pathways. Molecular docking and molecular dynamics simulations indicated moderate binding capacity between the active compounds and the screened target.

Conclusion

In this study, we successfully identified possible active ingredients and predicted potential targets and pathways for ZSW for the treatment of ALL. We provide a new strategy for further research on the molecular basis of ZSW biological effects in ALL. In addition, the potential active ingredients could provide new leads for drug discovery in ALL investigations.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cscr/10.2174/011574888X327937241129062944
2024-12-12
2025-01-22

  • From This Site

    /content/journals/cscr/10.2174/011574888X327937241129062944
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Zhang N. Wu J. Wang Q. Liang Y. Li X. Chen G. Ma L. Liu X. Zhou F. Global burden of hematologic malignancies and evolution patterns over the past 30 years. Blood Cancer J. 2023 13 1 82 10.1038/s41408‑023‑00853‑3 37193689
    [Google Scholar]
  2. Siegel R.L. Miller K.D. Wagle N.S. Jemal A. Cancer statistics, 2023. CA Cancer J. Clin. 2023 73 1 17 48 10.3322/caac.21763 36633525
    [Google Scholar]
  3. Pagliaro L. Chen S.J. Herranz D. Mecucci C. Harrison C.J. Mullighan C.G. Zhang M. Chen Z. Boissel N. Winter S.S. Roti G. Acute lymphoblastic leukaemia. Nat. Rev. Dis. Primers 2024 10 1 41 10.1038/s41572‑024‑00525‑x 38871740
    [Google Scholar]
  4. den Boer M.L. Cario G. Moorman A.V. Boer J.M. de Groot-Kruseman H.A. Fiocco M. Escherich G. Imamura T. Yeoh A. Sutton R. Dalla-Pozza L. Kiyokawa N. Schrappe M. Roberts K.G. Mullighan C.G. Hunger S.P. Vora A. Attarbaschi A. Zaliova M. Elitzur S. Cazzaniga G. Biondi A. Loh M.L. Pieters R. Outcomes of paediatric patients with B-cell acute lymphocytic leukaemia with ABL-class fusion in the pre-tyrosine-kinase inhibitor era: A multicentre, retrospective, cohort study. Lancet Haematol. 2021 8 1 e55 e66 10.1016/S2352‑3026(20)30353‑7 33357483
    [Google Scholar]
  5. Abou Dalle I. Atoui A. Bazarbachi A. The elephant in the room: AML relapse post allogeneic hematopoietic cell transplantation. Front. Oncol. 2022 11 793274 10.3389/fonc.2021.793274 35047405
    [Google Scholar]
  6. Tan Z. Kan C. Wong M. Sun M. Liu Y. Yang F. Wang S. Zheng H. Regulation of malignant myeloid leukemia by mesenchymal stem cells. Front. Cell Dev. Biol. 2022 10 857045 10.3389/fcell.2022.857045 35756991
    [Google Scholar]
  7. Park C.S. Yoshihara H. Gao Q. Qu C. Iacobucci I. Ghate P.S. Connelly J.P. Pruett-Miller S.M. Wagner B. Robinson C.G. Mishra A. Peng J. Yang L. Rankovic Z. Finkelstein D. Luger S. Litzow M. Paietta E.M. Hebbar N. Velasquez M.P. Mullighan C.G. Stromal-induced epithelial-mesenchymal transition induces targetable drug resistance in acute lymphoblastic leukemia. Cell Rep. 2023 42 7 112804 10.1016/j.celrep.2023.112804 37453060
    [Google Scholar]
  8. Fallati A. Di Marzo N. D’Amico G. Dander E. Mesenchymal stromal cells (MSCs): An ally of B-cell acute Lymphoblastic Leukemia (B-ALL) cells in disease maintenance and progression within the bone marrow Hematopoietic Niche. Cancers (Basel) 2022 14 14 3303 10.3390/cancers14143303 35884364
    [Google Scholar]
  9. Peter Muiruri K. Zhong J. Yao B. Lai R. Luo L. Bioactive peptides from scorpion venoms: Therapeutic scaffolds and pharmacological tools. Chin. J. Nat. Med. 2023 21 1 19 35 10.1016/S1875‑5364(23)60382‑6 36641229
    [Google Scholar]
  10. Ma Y. Zhou K. Fan J. Sun S. Traditional Chinese medicine: Potential approaches from modern dynamical complexity theories. Front. Med. 2016 10 1 28 32 10.1007/s11684‑016‑0434‑2 26809465
    [Google Scholar]
  11. Tavassoly I. Goldfarb J. Iyengar R. Systems biology primer: The basic methods and approaches. Essays Biochem. 2018 62 4 487 500 10.1042/EBC20180003 30287586
    [Google Scholar]
  12. Schubert M. Klinger B. Klünemann M. Sieber A. Uhlitz F. Sauer S. Garnett M.J. Blüthgen N. Saez-Rodriguez J. Perturbation-response genes reveal signaling footprints in cancer gene expression. Nat. Commun. 2018 9 1 20 10.1038/s41467‑017‑02391‑6 29295995
    [Google Scholar]
  13. Ru J. Li P. Wang J. Zhou W. Li B. Huang C. Li P. Guo Z. Tao W. Yang Y. Xu X. Li Y. Wang Y. Yang L. TCMSP: A database of systems pharmacology for drug discovery from herbal medicines. J. Cheminform. 2014 6 1 13 10.1186/1758‑2946‑6‑13 24735618
    [Google Scholar]
  14. Daina A. Michielin O. Zoete V. SwissTargetPrediction: Updated data and new features for efficient prediction of protein targets of small molecules. Nucleic Acids Res. 2019 47 W1 W357 W364 10.1093/nar/gkz382 31106366
    [Google Scholar]
  15. Fishilevich S. Nudel R. Rappaport N. Hadar R. Plaschkes I. Iny Stein T. Rosen N. Kohn A. Twik M. Safran M. Lancet D. Cohen D. GeneHancer: Genome-wide integration of enhancers and target genes in GeneCards. Database (Oxford) 2017 2017 bax028 10.1093/database/bax028 28605766
    [Google Scholar]
  16. Demeter-Haludka V. Kovács M. Petrus A. Patai R. Muntean D.M. Siklós L. Végh Á. Examination of the role of mitochondrial morphology and function in the cardioprotective effect of sodium nitrite administered 24 h before Ischemia/Reperfusion injury. Front. Pharmacol. 2018 9 286 10.3389/fphar.2018.00286 29643809
    [Google Scholar]
  17. Moulder R. Bhosale S.D. Goodlett D.R. Lahesmaa R. Analysis of the plasma proteome using iTRAQ and TMT‐based Isobaric labeling. Mass Spectrom. Rev. 2018 37 5 583 606 10.1002/mas.21550 29120501
    [Google Scholar]
  18. Gruszka A.M. Valli D. Alcalay M. Wnt signalling in acute myeloid leukaemia. Cells 2019 8 11 1403 10.3390/cells8111403 31703382
    [Google Scholar]
  19. El-Dydamony N.M. Abdelnaby R.M. Abdelhady R. Ali O. Fahmy M.I. R Fakhr Eldeen R. Helwa A.A. Helwa A.A. Pyrimidine-5-carbonitrile based potential anticancer agents as apoptosis inducers through PI3K/AKT axis inhibition in leukaemia K562. J. Enzyme Inhib. Med. Chem. 2022 37 1 895 911 10.1080/14756366.2022.2051022 35345960
    [Google Scholar]
  20. Shayo C. Legnazzi B.L. Monczor F. Fernández N. Riveiro M.E. Baldi A. Davio C. The time-course of cyclic AMP signaling is critical for leukemia U-937 cell differentiation. Biochem. Biophys. Res. Commun. 2004 314 3 798 804 10.1016/j.bbrc.2003.12.166 14741706
    [Google Scholar]
  21. García-Algarra J. Pastor J.M. Iriondo J.M. Galeano J. Ranking of critical species to preserve the functionality of mutualistic networks using the k -core decomposition. PeerJ 2017 5 e3321 10.7717/peerj.3321 28533969
    [Google Scholar]
  22. Terwilliger T. Abdul-Hay M. Acute lymphoblastic leukemia: A comprehensive review and 2017 update. Blood Cancer J. 2017 7 6 e577 10.1038/bcj.2017.53 28665419
    [Google Scholar]
  23. De Kouchkovsky I. Abdul-Hay M. ‘Acute myeloid leukemia: A comprehensive review and 2016 update’. Blood Cancer J. 2016 6 7 e441 10.1038/bcj.2016.50 27367478
    [Google Scholar]
  24. Frey N.V. Shaw P.A. Hexner E.O. Pequignot E. Gill S. Luger S.M. Mangan J.K. Loren A.W. Perl A.E. Maude S.L. Grupp S.A. Shah N.N. Gilmore J. Lacey S.F. Melenhorst J.J. Levine B.L. June C.H. Porter D.L. Optimizing chimeric antigen receptor T-cell therapy for adults with acute lymphoblastic leukemia. J. Clin. Oncol. 2020 38 5 415 422 10.1200/JCO.19.01892 31815579
    [Google Scholar]
  25. Winer E.S. Stone R.M. Novel therapy in Acute myeloid leukemia (AML): Moving toward targeted approaches. Ther. Adv. Hematol. 2019 10 2040620719860645 10.1177/2040620719860645 31321011
    [Google Scholar]
  26. Forte D. García-Fernández M. Sánchez-Aguilera A. Stavropoulou V. Fielding C. Martín-Pérez D. López J.A. Costa A.S.H. Tronci L. Nikitopoulou E. Barber M. Gallipoli P. Marando L. Fernández de Castillejo C.L. Tzankov A. Dietmann S. Cavo M. Catani L. Curti A. Vázquez J. Frezza C. Huntly B.J. Schwaller J. Méndez-Ferrer S. Bone marrow mesenchymal stem cells support acute myeloid leukemia bioenergetics and enhance antioxidant defense and escape from chemotherapy. Cell Metab. 2020 32 5 829 843.e9 10.1016/j.cmet.2020.09.001 32966766
    [Google Scholar]
  27. Yuan H. Ma Q. Cui H. Liu G. Zhao X. Li W. Piao G. How can synergism of traditional medicines benefit from network pharmacology? Molecules 2017 22 7 1135 10.3390/molecules22071135 28686181
    [Google Scholar]
  28. Zhang R. Zhu X. Bai H. Ning K. Network pharmacology databases for traditional chinese medicine: Review and assessment. Front. Pharmacol. 2019 10 123 10.3389/fphar.2019.00123 30846939
    [Google Scholar]
  29. Sun S. Li X. Ren A. Du M. Du H. Shu Y. Zhu L. Wang W. Choline and betaine consumption lowers cancer risk: A meta-analysis of epidemiologic studies. Sci. Rep. 2016 6 1 35547 10.1038/srep35547 27759060
    [Google Scholar]
  30. Phi L.T.H. Sari I.N. Wijaya Y.T. Kim K.S. Park K. Cho A.E. Kwon H.Y. Ginsenoside Rd inhibits the metastasis of colorectal cancer via epidermal growth factor receptor signaling axis. IUBMB Life 2019 71 5 601 610 10.1002/iub.1984 30576064
    [Google Scholar]
  31. Terasaki M. Mima M. Kudoh S. Endo T. Maeda H. Hamada J. Osada K. Miyashita K. Mutoh M. Glycine and succinic acid are effective indicators of the suppression of epithelial-mesenchymal transition by fucoxanthinol in colorectal cancer stem-like cells. Oncol. Rep. 2018 40 1 414 424 10.3892/or.2018.6398 29693702
    [Google Scholar]
  32. Ertugrul B. Iplik E.S. Cakmakoglu B. In vitro inhibitory effect of succinic acid on T-Cell acute Lymphoblastic leukemia cell lines. Arch. Med. Res. 2021 52 3 270 276 10.1016/j.arcmed.2020.10.022 33199038
    [Google Scholar]
  33. Watanabe M. Maemura K. Oki K. Shiraishi N. Shibayama Y. Katsu K. Gamma-aminobutyric acid (GABA) and cell proliferation: Focus on cancer cells. Histol. Histopathol. 2006 21 10 1135 1141 10.14670/HH‑21.1135 16835836
    [Google Scholar]
  34. Xu X. Li B. Huang P. Wan X. Qin Y. Zhou L. Liu H. Bai H. Gao Y. Wang C. Meng X. Citrate induces apoptosis of the acute monocytic leukemia U937 cell line through regulation of HIF-1α signaling. Mol. Med. Rep. 2013 8 5 1379 1384 10.3892/mmr.2013.1702 24064771
    [Google Scholar]
  35. Wu X. Dai H. Xu C. Liu L. Li S. Citric acid modification of a polymer exhibits antioxidant and anti‐inflammatory properties in stem cells and tissues. J. Biomed. Mater. Res. A 2019 107 11 2414 2424 10.1002/jbm.a.36748 31180606
    [Google Scholar]
  36. Zheng H. Fu X. Shang J. Lu R. Ou Y. Chen C. Ginsenoside Rg1 protects rat bone marrow mesenchymal stem cells against ischemia induced apoptosis through miR-494-3p and ROCK-1. Eur. J. Pharmacol. 2018 822 154 167 10.1016/j.ejphar.2018.01.001 29307726
    [Google Scholar]
  37. Sattari M. Islambulchilar M. Asvadi I. Sanaat Z. Esfahani A. Effect of taurine on attenuating chemotherapy-induced adverse effects in acute lymphoblastic leukemia. J. Cancer Res. Ther. 2015 11 2 426 432 10.4103/0973‑1482.151933 26148612
    [Google Scholar]
  38. Han J. Xia J. Zhang L. Cai E. Zhao Y. Fei X. Jia X. Yang H. Liu S. Studies of the effects and mechanisms of ginsenoside Re and Rk3 on myelosuppression induced by cyclophosphamide. J. Ginseng Res. 2019 43 4 618 624 10.1016/j.jgr.2018.07.009 31695568
    [Google Scholar]
  39. Cao Z.X. Wen Y. He J.L. Huang S.Z. Gao F. Guo C.J. Liu Q.Q. Zheng S.W. Gong D.Y. Li Y.Z. Zhang R.Q. Chen J.P. Peng C. Isoliquiritigenin, an orally available natural FLT3 inhibitor from Licorice, exhibits selective anti–acute myeloid leukemia efficacy in vitro and in vivo. Mol. Pharmacol. 2019 96 5 589 599 10.1124/mol.119.116129 31462456
    [Google Scholar]
  40. Kirkland J.B. Niacin status and treatment-related leukemogenesis. Mol. Cancer Ther. 2009 8 4 725 732 10.1158/1535‑7163.MCT‑09‑0042 19372544
    [Google Scholar]
  41. Marquez-Curtis L.A. Shirvaikar N. Turner A.R. Mirza I. Surmawala A. Larratt L.M. Janowska-Wieczorek A. Membrane type-1 matrix Metalloproteinase expression in acute Myeloid leukemia and its upregulation by tumor Necrosis factor-α. Cancers (Basel) 2012 4 3 743 762 10.3390/cancers4030743 24213464
    [Google Scholar]
  42. Li Z.J. Chen Z.X. Cen J.N. He J. Qiu Q.C. Direct contact with bone marrow stromal cells promotes the invasions of SHI-1 leukemia cells. Chin. Med. J. (Engl.) 2013 126 14 2731 2735 23876905
    [Google Scholar]
  43. Jahangiri B. Khalaj-Kondori M. Asadollahi E. Purrafee Dizaj L. Sadeghizadeh M. MSC-Derived exosomes suppress colorectal cancer cell proliferation and metastasis via miR-100/mTOR/miR-143 pathway. Int. J. Pharm. 2022 627 122214 10.1016/j.ijpharm.2022.122214 36152993
    [Google Scholar]
  44. Man C.H. Zeng X. Lam W. Ng T.C.C. Kwok T.H. Dang K.C.C. Leung T.W.Y. Ng N.K.L. Lam S.S.Y. Cher C.Y. Leung A.Y.H. Regulation of proton partitioning in kinase-activating acute myeloid leukemia and its therapeutic implication. Leukemia 2022 36 8 1990 2001 10.1038/s41375‑022‑01606‑0 35624145
    [Google Scholar]
  45. Jia Z. Zhu H. Sun H. Hua Y. Zhang G. Jiang J. Wang X. Adipose Mesenchymal stem cell-derived Exosomal microRNA-1236 reduces resistance of breast cancer cells to Cisplatin by suppressing SLC9A1 and the Wnt/β-Catenin signaling. Cancer Manag. Res. 2020 12 8733 8744 10.2147/CMAR.S270200 33061571
    [Google Scholar]
  46. Bonilla X. Vanegas N.D.P. Vernot J.P. Acute leukemia induces senescence and impaired Osteogenic differentiation in Mesenchymal stem cells endowing leukemic cells with functional advantages. Stem Cells Int. 2019 2019 1 16 10.1155/2019/3864948 31065273
    [Google Scholar]
  47. Bui T.M. Wiesolek H.L. Sumagin R. ICAM-1: A master regulator of cellular responses in inflammation, injury resolution, and tumorigenesis. J. Leukoc. Biol. 2020 108 3 787 799 10.1002/JLB.2MR0220‑549R 32182390
    [Google Scholar]
  48. Jamil K. Jayaraman A. Rao R. Raju S. In silico evidence of signaling pathways of notch mediated networks in leukemia. Comput. Struct. Biotechnol. J. 2012 1 2 e201207005 10.5936/csbj.201207005 24688641
    [Google Scholar]
  49. Sharma M. Ross C. Srivastava S. Ally to adversary: Mesenchymal stem cells and their transformation in leukaemia. Cancer Cell Int. 2019 19 1 139 10.1186/s12935‑019‑0855‑5 31139016
    [Google Scholar]
  50. Puerto-Camacho P. Díaz-Martín J. Olmedo-Pelayo J. Bolado-Carrancio A. Salguero-Aranda C. Jordán-Pérez C. Esteban-Medina M. Álamo-Álvarez I. Delgado-Bellido D. Lobo-Selma L. Dopazo J. Sastre A. Alonso J. Grünewald T.G.P. Bernabeu C. Byron A. Brunton V.G. Amaral A.T. Álava E.D. Endoglin and MMP14 contribute to ewing sarcoma spreading by modulation of cell–matrix interactions. Int. J. Mol. Sci. 2022 23 15 8657 10.3390/ijms23158657 35955799
    [Google Scholar]
  51. Yang Y. Yang Y. Shen Y. Liu J. Zeng Y. Wei C. Liu C. Pan Y. Guo Q. Zhong F. Guo L. Liu W. Exploring the pharmacological mechanisms of Shuanghuanglian against T-cell acute lymphoblastic leukaemia through network pharmacology combined with molecular docking and experimental validation. Pharm. Biol. 2023 61 1 259 270 10.1080/13880209.2023.2168703 36656546
    [Google Scholar]
  52. J Liu Exploring the mechanism of physcion-1-O-β-D-monoglucoside against acute lymphoblastic leukaemia based on network pharmacology and experimental validation Heliyon 2023 9 3 e14009 10.1016/j.heliyon.2023.e14009
    [Google Scholar]
/content/journals/cscr/10.2174/011574888X327937241129062944
Loading
Mechanism of Zhengsui Wan in the Treatment of Acute Lymphoblastic Leukemia Based on Network Pharmacology and Experimental Validation
Bentham Science Publishers ; https://doi.org/10.2174/011574888X327937241129062944
/content/journals/cscr/10.2174/011574888X327937241129062944
/content/journals/cscr/10.2174/011574888X327937241129062944
Loading

Data & Media loading...


  • Article Type:     Research Article
Keywords: ZhengSui Wan ; network pharmacology ; acute lymphoblastic leukemia ; molecular docking ; molecular dynamics simulation

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test